Sugi Predict

Sugi Predict / Compounds / SCHEMBL1615880

SCHEMBL1615880

SCHEMBL1615880

O=C(NOCC1CC1)c1ncc2cncn2c1Nc1ccc(I)cc1F

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 5/20 0.76
▸ MAP2K1 Q02750 13/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ RAF1 P04049 1/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ CSNK2A2 P19784 1/20 0.46
▸ MAP2K2 P36507 1/20 0.46
▸ CSNK2B P67870 1/20 0.46
▸ CSNK2A1 P68400 1/20 0.46
▸ CSNK2A3 Q8NEV1 1/20 0.46
▸ AURKC Q9UQB9 1/20 0.46
▸ CAMK2A Q9UQM7 1/20 0.46
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29683838 1.00 KCNH2 (0.76) KCNH2MAP2K1CYP2C9MEN1KMT2A
SCHEMBL18789024 0.90 KCNH2 (0.61) KCNH2MAP2K1CYP2C9MEN1KMT2A
SCHEMBL1616115 0.90 KCNH2 (0.61) KCNH2MAP2K1CYP2C9MEN1KMT2A
SCHEMBL29683743 0.90 KCNH2 (0.61) KCNH2MAP2K1CYP2C9MEN1KMT2A
SCHEMBL29683583 0.87 KCNH2 (0.81) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19
SCHEMBL1615230 0.87 KCNH2 (0.81) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19
SCHEMBL29683658 0.86 KCNH2 (1.00) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19
SCHEMBL1615889 0.86 KCNH2 (1.00) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19
SCHEMBL18789312 0.86 KCNH2 (0.87) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19
SCHEMBL1615088 0.85 KCNH2 (0.69) KCNH2MAP2K1CYP2C9MAP2K2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690101-B1 5-Anilinoimidazopyridines and Methods of Use GENENTECH INC (US) 2015-06-24 — — EP claimed
EP-2690101-A1 5-Anilinoimidazopyridines and Methods of Use Genentech, Inc. (US) 2014-01-29 — — EP claimed
EP-2222675-B1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH INC (US) 2013-09-11 — — EP claimed
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2012-12-06 — — US claimed
US-8288408-B2 5-anilinoimidazopyridines and methods of use GENENTECH, INC. (US) 2012-10-16 — — US claimed
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2011-06-30 — — US claimed
US-10946093-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2021-03-16 — — US disclosed
US-10946093-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2021-03-16 — — US disclosed
US-10646567-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2020-05-12 — — US disclosed
US-10646567-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors GENENTECH, INC. (US) 2020-05-12 — — US disclosed
EP-3169361-B1 COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS HOFFMANN LA ROCHE (CH) 2019-06-19 — — EP disclosed
EP-3169361-B1 COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS HOFFMANN LA ROCHE (CH) 2019-06-19 — — EP disclosed
EP-2739358-B1 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS HOFFMANN LA ROCHE (CH) 2018-11-28 — — EP disclosed
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2011-06-30 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10946093-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors CD274, PDCD1, PDCD1LG2 KCNH2 4598/4885MAP2K1 13/4885CYP2C9 4843/4885
US-10646567-B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors CD274, PDCD1, PDCD1LG2 KCNH2 4598/4885MAP2K1 13/4885CYP2C9 4843/4885
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP KCNH2 2040/4885MAP2K1 999/4885CYP2C9 3917/4885
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP KCNH2 2040/4885MAP2K1 999/4885CYP2C9 3917/4885
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, MAP3K5, MAPKAPK5 KCNH2 1382/4885MAP2K1 64/4885CYP2C9 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.